FDA approves Scibase's melanoma detection device: 3 things to know

The Food and Drug Administration on Thursday approved Scibase's skin cancer detection device Nevisense.

Here are three things to know.

1. Nevisense is intended to help clinicians detect early stages of malignant melanoma.
   
   

2. Clinicians may use the device to further assess suspicious skin lesions with one or more characteristics of melanoma before conducting a biopsy.
   
   

3. The device, which uses electrical signals to measure and assess the skin, should not be used to confirm a clinical melanoma diagnosis.
   
   

More articles on supply chain:

UPS to freeze 70k workers' pensions: 3 things to know
Philips to acquire Spectranetics devicemaker for $2.2B: 5 things to know
Valeant 'most exposed' to generic competition by FDA's new drug list, says analyst